Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study.

Pinato DJ, Mauri FA, Spina P, Cain O, Siddique A, Goldin R, Victor S, Pizio C, Akarca AU, Boldorini RL, Mazzucchelli L, Black JRM, Shetty S, Marafioti T, Sharma R.

Br J Cancer. 2019 May;120(11):1033-1036. doi: 10.1038/s41416-019-0466-x. Epub 2019 May 7.

2.

PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity.

Black JR, Goldin RD, Foxton M, Marafioti T, Akarca AU, Pria AD, Brock C, Bower M, Pinato DJ.

Immunotherapy. 2019 May;11(7):585-590. doi: 10.2217/imt-2018-0187.

PMID:
30943859
3.

Role of Epstein-Barr virus in transformation of follicular lymphoma to diffuse large B-cell lymphoma: a case report and review of the literature.

Granai M, Ambrosio MR, Akarca A, Mundo L, Vergoni F, Santi R, Mancini V, di Stefano G, Amato T, Bellan C, Puccini B, Sorrentino E, Naresh KN, Leoncini L, Marafioti T, Lazzi S.

Haematologica. 2019 Jun;104(6):e269-e273. doi: 10.3324/haematol.2018.215053. Epub 2019 Mar 7. No abstract available.

4.

Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours.

Rizzo FM, Vesely C, Childs A, Marafioti T, Khan MS, Mandair D, Cives M, Ensell L, Lowe H, Akarca AU, Luong T, Caplin M, Toumpanakis C, Krell D, Thirlwell C, Silvestris F, Hartley JA, Meyer T.

Br J Cancer. 2019 Feb;120(3):294-300. doi: 10.1038/s41416-018-0367-4. Epub 2019 Jan 14.

PMID:
30636773
5.

LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L.

Taraborrelli L, Peltzer N, Montinaro A, Kupka S, Rieser E, Hartwig T, Sarr A, Darding M, Draber P, Haas TL, Akarca A, Marafioti T, Pasparakis M, Bertin J, Gough PJ, Bouillet P, Strasser A, Leverkus M, Silke J, Walczak H.

Nat Commun. 2018 Sep 25;9(1):3910. doi: 10.1038/s41467-018-06155-8.

6.

Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type.

Lo Bello G, Akarca AU, Ambrosio MR, Agostinelli C, Molina-Kirsch H, Ramsay A, Rodriguez-Justo M, Pugh M, Zhao S, DeLisser M, Sabattini E, Dojcinov S, Pileri SA, Natkunam Y, Leoncini L, Marafioti T.

Virchows Arch. 2018 Dec;473(6):749-757. doi: 10.1007/s00428-018-2434-x. Epub 2018 Aug 27.

7.

Functional immune characterization of HIV-associated non-small-cell lung cancer.

Pinato DJ, Kythreotou A, Mauri FA, Suardi E, Allara E, Shiner RJ, Akarca AU, Trivedi P, Gupta N, Dalla Pria A, Marafioti T, Oliveri P, Newsom-Davis T, Bower M.

Ann Oncol. 2018 Jun 1;29(6):1486-1488. doi: 10.1093/annonc/mdy125. No abstract available.

8.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C.

Nature. 2018 Feb 8;554(7691):264. doi: 10.1038/nature25161. Epub 2017 Dec 20.

PMID:
29258292
9.

Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia.

Ghorani E, Kaur B, Fisher RA, Short D, Joneborg U, Carlson JW, Akarca A, Marafioti T, Quezada SA, Sarwar N, Seckl MJ.

Lancet. 2017 Nov 25;390(10110):2343-2345. doi: 10.1016/S0140-6736(17)32894-5. No abstract available.

10.

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.

Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, Legut M, Cole DK, Sewell AK, Gritti G, Somja J, Piris MA, Peggs KS, Linch DC, Marafioti T, Pule MA.

Nat Med. 2017 Dec;23(12):1416-1423. doi: 10.1038/nm.4444. Epub 2017 Nov 13.

PMID:
29131157
11.

Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.

Linch M, Goh G, Hiley C, Shanmugabavan Y, McGranahan N, Rowan A, Wong YNS, King H, Furness A, Freeman A, Linares J, Akarca A, Herrero J, Rosenthal R, Harder N, Schmidt G, Wilson GA, Birkbak NJ, Mitter R, Dentro S, Cathcart P, Arya M, Johnston E, Scott R, Hung M, Emberton M, Attard G, Szallasi Z, Punwani S, Quezada SA, Marafioti T, Gerlinger M, Ahmed HU, Swanton C.

Ann Oncol. 2017 Oct 1;28(10):2472-2480. doi: 10.1093/annonc/mdx355.

12.

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.

Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.

13.

Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA.

Kato I, Nishinaka Y, Nakamura M, Akarca AU, Niwa A, Ozawa H, Yoshida K, Mori M, Wang D, Morita M, Ueno H, Shiozawa Y, Shiraishi Y, Miyano S, Gupta R, Umeda K, Watanabe K, Koh K, Adachi S, Heike T, Saito MK, Sanada M, Ogawa S, Marafioti T, Watanabe A, Nakahata T, Enver T.

Blood. 2017 Jun 8;129(23):3126-3129. doi: 10.1182/blood-2016-06-721712. Epub 2017 Apr 19. No abstract available.

14.

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.

Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE, Havenith CE, Levy JN, Tiberghien A, Masterson LA, Barry C, D'Hooge F, Marafioti T, Parren PW, Williams DG, Howard PW, van Berkel PH, Hartley JA.

Mol Cancer Ther. 2016 Nov;15(11):2709-2721. Epub 2016 Aug 17.

15.

Cell cycle status in AML blast cells from peripheral blood, bone marrow aspirates and trephines and implications for biological studies and treatment.

Sellar RS, Fraser L, Khwaja A, Gale RE, Marafioti T, Akarca A, Hubank M, Brooks T, Stoeber K, Williams G, Linch DC.

Br J Haematol. 2016 Jul;174(2):275-9. doi: 10.1111/bjh.14055. Epub 2016 Apr 8.

PMID:
27061724
16.

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.

McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C.

Science. 2016 Mar 25;351(6280):1463-9. doi: 10.1126/science.aaf1490. Epub 2016 Mar 3.

17.

BRAF(V600E) mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients.

Sellar RS, Fend F, Akarca AU, Agostinelli C, Shende V, Quintanilla-Martínez L, Stein H, Pileri SA, Linch D, Marafioti T.

Br J Haematol. 2015 Jul;170(2):282-5. doi: 10.1111/bjh.13291. Epub 2015 Mar 10. No abstract available.

PMID:
25758903
18.

Intracellular TCR-signaling pathway: novel markers for lymphoma diagnosis and potential therapeutic targets.

Agostinelli C, Rizvi H, Paterson J, Shende V, Akarca AU, Agostini E, Fuligni F, Righi S, Spagnolo S, Piccaluga PP, Clark EA, Pileri SA, Marafioti T.

Am J Surg Pathol. 2014 Oct;38(10):1349-59. doi: 10.1097/PAS.0000000000000309.

PMID:
25118816
19.

BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia.

Akarca AU, Shende VH, Ramsay AD, Diss T, Pane-Foix M, Rizvi H, Calaminici MR, Grogan TM, Linch D, Marafioti T.

Br J Haematol. 2013 Sep;162(6):848-51. doi: 10.1111/bjh.12429. Epub 2013 Jul 13. No abstract available.

PMID:
23848818
20.

Plasma membrane cholesterol content affects nitric oxide diffusion dynamics and signaling.

Miersch S, Espey MG, Chaube R, Akarca A, Tweten R, Ananvoranich S, Mutus B.

J Biol Chem. 2008 Jul 4;283(27):18513-21. doi: 10.1074/jbc.M800440200. Epub 2008 Apr 29.

Supplemental Content

Loading ...
Support Center